Inclusion body myositis: an update.

Journal

Current opinion in rheumatology

ISSN: 1531-6963

Titre abrégé: Curr Opin Rheumatol

Pays: United States

ID NLM: 9000851

Informations de publication

Date de publication:
22 Oct 2024

Historique:

medline: 29 10 2024

pubmed: 29 10 2024

entrez: 29 10 2024

Statut: aheadofprint

Résumé

To review recent advances in our understanding of the epidemiology, pathophysiology, and management of inclusion body myositis (IBM). Recent epidemiologic studies have highlighted the morbidity and mortality associated with IBM, including the impact of dysphagia. Multiomic analyses of IBM tissues have identified new pathogenic pathways and biomarkers for use in clinical trials. New diagnostic criteria and outcome measures have been proposed to improve clinical trial design. Ongoing clinical trials are targeting T cells and autophagy. Improvements in our understanding of IBM pathogenesis are identifying new pathways and biomarkers that need validation in larger cohorts. Exercise remains the primary therapeutic modality available, and new treatment targets are needed.

Identifiants

DOI: 10.1097/BOR.0000000000001060 PMID: 39469805

pubmed: 39469805

doi: 10.1097/BOR.0000000000001060

pii: 00002281-990000000-00149

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Lindgren U, Pullerits R, Lindberg C, Oldfors A. Epidemiology, survival, and clinical characteristics of inclusion body myositis. Ann Neurol 2022; 92:201–212.

Shelly S, Mielke MM, Mandrekar J, et al. Epidemiology and natural history of inclusion body myositis. Neurology 2021; 96:e2653–e2661.

Lindgren U, Hedberg-Oldfors C, Pullerits R, et al. Inclusion body myositis with early onset: a population-based study. J Neurol 2023; 270:5483–5492.

Naddaf E, Shelly S, Mandrekar J, et al. Survival and associated comorbidities in inclusion body myositis. Rheumatology 2021; 61:2016–2024.

Senn KC, Thiele S, Kummer K, et al. Cost of illness in inclusion body myositis: results from a cross-sectional study in Germany. Orphanet J Rare Dis 2023; 18:337.

Senn KC, Thiele S, Kummer K, et al. Patient-reported health-related quality of life, anxiety and depression in patients with inclusion body myositis: a register-based cross-sectional study in Germany. J Clin Med 2023; 12:5051.

Senn KC, Thiele S, Gumbert L, et al. Inclusion body myositis—health-related quality of life and care situation during phases of the ‘patience journey’ in Germany: results from a qualitative study. Health Qual Life Outcomes 2023; 21:111.

Brokamp G, Hurst L, Hartog L, et al. Characterizing ventilatory muscle dysfunction in inclusion body myositis. Am J Phys Med Rehabil 2023; 102:427–432.

Michelle EH, Pinal-Fernandez I, Casal-Dominguez M, et al. Clinical subgroups and factors associated with progression in patients with inclusion body myositis. Neurology 2023; 100:e1406–e1417.

Diederichsen LP, Iversen LV, Nielsen CT, et al. Myositis-related autoantibody profile and clinical characteristics stratified by anticytosolic 5′-nucleotidase 1A status in connective tissue diseases. Muscle Nerve 2023; 68:73–80.

Paul P, Liewluck T, Ernste FC, et al. AnticN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis. Muscle Nerve 2021; 63:490–496.

Mavroudis I, Knights M, Petridis F, et al. Diagnostic accuracy of anti-CN1A on the diagnosis of inclusion body myositis. a hierarchical bivariate and Bayesian meta-analysis. J Clin Neuromusc Dis 2021; 23:31–38.

Lilleker JB, Naddaf E, Saris CGJ, et al. 272nd ENMC international workshop: 10 years of progress - revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16–18 June 2023, Hoofddorp, The Netherlands. Neuromuscul Disord 2024; 37:36–51.

Fortanier E, Delmont E, Kouton L, et al. Face to face: deciphering facial involvement in inclusion body myositis. J Neurol 2024; 271:410–418.

Taira K, Mori-Yoshimura M, Yamamoto T, et al. Clinical characteristics of dysphagic inclusion body myositis. Neuromusc Disord 2023; 33:133–138.

Ma AK, Dai F, Roy B. In-patient comorbidities in inclusion body myositis: a United States national in-patient sample-based study. Clin Exp Rheumatol 2023; 41:261–266.

Pinto MV, Laughlin RS, Klein CJ, et al. Inclusion body myositis: correlation of clinical outcomes with histopathology, electromyography and laboratory findings. Rheumatology 2021; 61:2504–2511.

Slater N, Sooda A, McLeish E, et al. High-resolution HLA genotyping in inclusion body myositis refines 8.1 ancestral haplotype association to DRB1∗03:01:01 and highlights pathogenic role of arginine-74 of DRβ1 chain. J Autoimmun 2024; 142:103150.

Greenberg SA, Pinkus JL, Kong SW, et al. Highly differentiated cytotoxic T cells in inclusion body myositis. Brain 2019; 142:2590–2604.

Matsubara S, Suzuki S, Komori T. Immunohistochemical phenotype of T cells invading muscle in inclusion body myositis. J Neuropathol Exp Neurol 2022; 81:825–835.

Greenberg SA, Pinkus JL, Amato AA, et al. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain 2016; 139:1348–1360.

McLeish E, Sooda A, Slater N, et al. Uncovering the significance of expanded CD8+ large granular lymphocytes in inclusion body myositis: Insights into T cell phenotype and functional alterations, and disease severity. Front Immunol 2023; 14:1153789.

McLeish E, Sooda A, Slater N, et al. Identification of distinct immune signatures in inclusion body myositis by peripheral blood immunophenotyping using machine learning models. Clin Transl Immunol 2024; 13:e1504.

Goyal NA, Coulis G, Duarte J, et al. Immunophenotyping of inclusion body myositis blood T and NK cells. Neurology 2022; 98:e1374–e1383.

Britson KA, Ling JP, Braunstein KE, et al. Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Sci Transl Med 2022; 14:eabi9196.

Lynch EM, Pittman S, Daw J, et al. Seeding competent TDP-43 persists in human patient and mouse muscle. Sci Transl Med 2024; (in press).

Wischnewski S, Thäwel T, Ikenaga C, et al. Cell type mapping of inflammatory muscle diseases highlights selective myofiber vulnerability in inclusion body myositis. Nat Aging 2024; 4:969–983.

Jensen KY, Nielsen JL, Aagaard P, et al. Effects of sporadic inclusion body myositis on skeletal muscle fibre type specific morphology and markers of regeneration and inflammation. Rheumatol Int 2024; 44:1077–1087.

Nelke C, Schroeter CB, Theissen L, et al. Senescent fibro-adipogenic progenitors are potential drivers of pathology in inclusion body myositis. Acta Neuropathol 2023; 146:725–745.

Johari M, Vihola A, Palmio J, et al. Comprehensive transcriptomic analysis shows disturbed calcium homeostasis and deregulation of T lymphocyte apoptosis in inclusion body myositis. J Neurol 2022; 269:4161–4173.

Ikenaga C, Date H, Kanagawa M, et al. Muscle transcriptomics shows overexpression of cadherin 1 in inclusion body myositis. Ann Neurol 2022; 91:317–328.

Lucchini M, De Arcangelis V, Santoro M, et al. Serum-circulating microRNAs in sporadic inclusion body myositis. Int J Mol Sci 2023; 24:11139.

Cantó-Santos J, Valls-Roca L, Tobías E, et al. Unravelling inclusion body myositis using a patient-derived fibroblast model. J Cachexia Sarcopenia Muscle 2023; 14:964–977.

Murakami A, Noda S, Kazuta T, et al. Metabolome and transcriptome analysis on muscle of sporadic inclusion body myositis. Ann Clin Transl Neurol 2022; 9:1602–1615.

Cantó-Santos J, Valls-Roca L, Tobías E, et al. Integrated multi-omics analysis for inferring molecular players in inclusion body myositis. Antioxidants 2023; 12:1639.

Symonds T, Randall J, Lloyd-Price L, et al. Study to assess content validity and interrater and intrarater reliability of the inclusion body myositis functional rating scale. Neurol Clin Pract 2023; 13:e200168.

Roy B, Zubair A, Petschke K, et al. Reliability of patient self-reports to clinician-assigned functional scores of inclusion body myositis. J Neurol Sci 2022; 436:120228.

Hunn S, Alfano L, Seiffert M, Weihl CC. Exploring hand and upper limb function in patients with inclusion body myositis (IBM). Neuromusc Disord 2023; 33:643–650.

Goyal NA, Greenberg SA, Cauchi J, et al. Correlations of disease severity outcome measures in inclusion body myositis. Neuromuscul Disord 2022; 32:800–805.

Laurent D, Riek J, Sinclair CDJ, et al. Longitudinal changes in MRI muscle morphometry and composition in people with inclusion body myositis. Neurology 2022; 99:e865–e876.

Reyngoudt H, Baudin P-Y, Caldas de Almeida Araújo E, et al. Effect of sirolimus on muscle in inclusion body myositis observed with magnetic resonance imaging and spectroscopy. J Cachexia Sarcopenia Muscle 2024; 15:1108–1120.

Quinn C, Moulton K, Farwell M, et al. Imaging with PET/CT of diffuse CD8 T-cell infiltration of skeletal muscle in patients with inclusion body myositis. Neurology 2023; 101:e1158–e1166.

Black C, Cai H, Shabbir A, Wang LH. Relationship between hand function and handheld ultrasound imaging in inclusion body myositis. J Clin Neuromuscul Dis 2024; 25:115–121.

Paramalingam S, Needham M, Mastaglia FL, Keen HI. A longitudinal study using B mode ultrasound and power Doppler as monitoring imaging tools in inclusion body myositis. Clin Exp Rheumatol 2024; 42:351–357.

Tani T, Imai S, Fushimi K. Increasing daily duration of rehabilitation for inpatients with sporadic inclusion body myositis may contribute to improvement in activities of daily living: a nationwide database cohort study. J Rehabil Med 2023; 55:jrm00386.

Williams E, Cooper I, Beer K, et al. Does inspiratory muscle training improve lung function and quality of life in people with inclusion body myositis? A pilot study. Neuromuscul Disord 2024; 37:6–12.

Johnson LG, Collier KE, Edwards DJ, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis 2009; 10:178–184.

Kuchinad K, Nadeem M, Mehta AK, et al. Palliative care utilization for hospitalized patients with inclusion body myositis: a nationwide study. J Clin Rheumatol 2023; 29:e130–e133.

Machado PM, McDermott MP, Blaettler T, et al. Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2023; 22:900–911.

Amato AA, Hanna MG, Machado PM, et al. Efficacy and safety of bimagrumab in sporadic inclusion body myositis. Neurology 2021; 96:e1595–e1607.

Benveniste O, Hogrel J-Y, Belin L, et al. Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. Lancet Rheumatol 2021; 3:e40–e48.

Connor SG, Fairchild TJ, Learmonth YC, et al. Testosterone treatment combined with exercise to improve muscle strength, physical function and quality of life in men affected by inclusion body myositis: a randomised, double-blind, placebo-controlled, crossover trial. PLoS One 2023; 18:e0283394.

Coudert JD, Slater N, Sooda A, et al. Immunoregulatory effects of testosterone supplementation combined with exercise training in men with inclusion body myositis: a double-blind, placebo-controlled, cross-over trial. Clin Transl Immunol 2022; 11:e1416.